Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study

Basit Öğe Kaydı
dc.authoridKorkmaz, Levent/0000-0001-6931-6896
dc.authoridBeypinar, Ismail/0000-0002-0853-4096
dc.authoridaraz, murat/0000-0002-4632-9501
dc.authoridArtac, Mehmet/0000-0003-2335-3354
dc.contributor.authorAraz, Murat
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorKorkmaz, Levent
dc.contributor.authorKoral, Lokman
dc.contributor.authorInci, Fatih
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorUysal, Mukremin
dc.date.accessioned2025-01-27T20:50:28Z
dc.date.available2025-01-27T20:50:28Z
dc.date.issued2019
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurposeWe aimed to investigate the efficacy of 0.25mg dose of palonosetron and granisetron in triplet antiemetic prophylaxis in breast cancer patients receiving HEC.MethodsPatients with nonmetastatic breast cancer who received HEC [doxorubicin or epirubicin plus cyclophosphamide (AC/EC)] were enrolled in the study. The prophylactic triplet antiemetic regimens were used according to the doctor's preference during the first cycle of HEC as intravenous dexamethasone and palonosetron 0.25mg or granisetron 3mg on day 1 as well as oral aprepitant (125mg on day 1 and 80mg on days 2 and 3).The primary endpoint was complete response rate (CR) on acute and delayed chemotherapy-induced nausea and vomiting (CINV), separately.ResultsA total of 118 female patients were included in the study. Patients received AC (83%), EC (3%), and dose-dense AC (14%) as adjuvant (88%) or neoadjuvant (12%). The majority of patients received palonosetron (59%) containing antiemetic treatment. The CR rate on acute and delayed vomiting was very high and not statistically different in both of the arms (acute 87% vs. 96%, p=0.089; delayed 90% vs. 92%, p=0.489), respectively. Nevertheless, the CR rate on either acute or delayed nausea was lower than vomiting (acute 51% vs. 51%; delayed 38% vs. 29%, p=0.203; respectively).ConclusionsThis is the second study that compared a 0.25mg dose of palonosetron with first-generation setron in triplet antiemetic prophylaxis in cancer patients receiving HEC. We could not find meaningful statistical differences between two arms, regarding CR rate on acute and delayed CINV.
dc.identifier.doi10.1007/s00280-019-03831-4
dc.identifier.endpage1097
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue6
dc.identifier.pmid30963213
dc.identifier.scopus2-s2.0-85064262849
dc.identifier.scopusqualityQ2
dc.identifier.startpage1091
dc.identifier.urihttps://doi.org/10.1007/s00280-019-03831-4
dc.identifier.urihttps://hdl.handle.net/20.500.12428/25501
dc.identifier.volume83
dc.identifier.wosWOS:000467025300010
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofCancer Chemotherapy and Pharmacology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectBreast cancer
dc.subjectGranisetron
dc.subjectHigh emetogenic chemotherapy
dc.subjectPalonosetron
dc.subjectTriplet antiemetic
dc.titleComparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu